Usona Institute

Peak Experiences & Psychedelics North America

Overview

Spearheading research of psychedelics

Usona Institute leads clinical research on psilocybin-assisted therapy for treatment-resistant depression and other mental health conditions, building the evidence base for psychedelic medicine.

Founded: 2014

Founders: Bill Linton, Malynn Utzinger

Non-profit Policy & Advocacy

Recent coverage

View all coverage

Policy & Regulation2026-04-24

Usona Institute Awarded FDA Commissioner's National Priority Voucher for PSIL201 Psilocybin in Major Depressive Disorder

FDA awarded a Commissioner's National Priority Voucher (CNPV) to Usona Institute for PSIL201, a psilocybin treatment in Phase 3 for major depressive disorder. The award was announced concurrently with the Compass and Transcend CNPVs.